Table 1.

Detailed medications and treatment

Time periods	Treatment	Line	Cycle	RECIST	PFS (month)
From November 2014 to January 2015	Fosfamide 2 g days 1–3 and pemetrexed 800 mg day 4, every 21 days	1	2	PD	–
From March 17 to April 18, 2015	Navelbine 40 mg day 1/day 8 and carboplatin 400 mg day 2 and bevacizumab 400 mg day 1, every 21 days	2	6	PR	4
From May 12 to July 29, 2015	Navelbine 40 mg day 1/day 8 and oxaliplatin 150 mg day 2 and bevacizumab 400 mg day 1, every 21 days
From September 2 to October 19, 2015	Gemcitabine 1.8 g day 1/day 8 and bevacizumab 400 mg day 1, every 21 days Gemcitabine 1.8 g day 1, every 21 days	3	1 1	PD	–
From November 9, 2015, to October 12, 2016	Paclitaxel 210 mg day 1 and bevacizumab 400 mg day 1, every 21 days	4	15	PR	14
From November 11 to December 7, 2016	Paclitaxel 180 mg day 1 and oxaliplatin 150 mg day 1 and bevacizumab 400 mg day 1, every 21 days		2	PD	–
From January 14 to February 14, 2017	Gefitinib 250 mg/day and bevacizumab 400 mg day 1, every 21 days	5	1	PD	–
From March 3, 2017 to until now	Afatinib 40 mg/day and bevacizumab 400 mg day 1, every 21 days	6	4	PR	6

Abbreviations: PD, progressive disease; PFS, progression-free survival; PR, partial response; RECIST, response evaluation criteria in solid tumors.